Logo Image
|Articles|April 1, 2001

Pharmaceutical Executive

  • Pharmaceutical Executive-04-01-2001
  • Volume 0
  • Issue 0

Regulation: OK After All

Author(s)Kevin Gopal

London-The National Institute of Clinical Excellence (NICE) has decided that Roche's Xenical (orlistat) should be available from the National Health Service for managing obesity and its related problems, but it should not be viewed as a slimming pill.

Articles in this issue

over 25 years ago

Internet DTC - Minding Your P's & Q's

over 25 years ago

Regulation: Two-Track Plan

over 25 years ago

Policy: Tectonic Shift

over 25 years ago

Liberated?

over 25 years ago

A Matter of Taste

over 25 years ago

Partnerships: Bargaining Biotechs

over 25 years ago

Pediatric Mandate

over 25 years ago

Genentech's Passion for Patients

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more